Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01456533

Acronym

COMED

Enrollment

300

Registered

2011-10-20

Start date

2011-10-31

Completion date

2015-04-30

Last updated

2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypernatremia, Hyponatremia

Keywords

hyponatremia, hypernatremia

Brief summary

Background: Hypo- and hypernatremia are common in hospitalized patients. The differential diagnosis of dysnatremia is challenging. Osmotically inadequate secretion of antidiuretic hormone (ADH) is the predominant mechanism in most dysnatremic disorders. ADH measurement is cumbersome. It is derived from a larger precursor peptide along with copeptin, which is a more stable peptide directly mirroring the production of ADH. Objective: To evaluate the additional value of copeptin to improve a currently used algorithm in the differential diagnosis of (A) severe hypoosmolar hypo- and (B) severe hypernatremia. Design: Prospective observational study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 110 Years

Healthy volunteers

Inclusion criteria

* hyponatremia \<125 or hypernatremia \>155 mmol/L

Exclusion criteria

* no informed consent

Design outcomes

Primary

Measure	Time frame	Description
diagnostic accuracy of copeptin within hospital stay	participants will be followed for up to 1 year	diagnostic accuracy will be determined by receiver operated curve (ROC) analysis. The study is powered to detect a difference of copeptin levels between patients with partial central diabetes insipidus (DI) and patients with primary polydipsia.

Countries

Switzerland

Outcome results